Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib + Paclitaxel + Carboplatin as Neoadjuvant Therapy in Ovarian Cancer
NCT05276973Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of ipatasertib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Started Sep 2022; status: active, not recruiting.
02
Drugs
ipatasertib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05276973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05276973.